{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:01:34Z","timestamp":1792116094013,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Avadel Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40263-022-00904-6","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:02:36Z","timestamp":1649149356000},"page":"377-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial"],"prefix":"10.1007","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct02720744","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Thomas","family":"Roth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dauvilliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thorpy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clete","family":"Kushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce C.","family":"Corser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Dubow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6548-2042","authenticated-orcid":false,"given":"David","family":"Seiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"904_CR1","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","volume":"3","author":"BR Kornum","year":"2017","unstructured":"Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100.","journal-title":"Nat Rev Dis Primers"},{"key":"904_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/sleep\/30.1.13","volume":"30","author":"JRWT Longstreth","year":"2007","unstructured":"Longstreth JRWT, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep. 2007;30:13\u201326.","journal-title":"Sleep"},{"key":"904_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","volume":"369","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369:499\u2013511.","journal-title":"Lancet"},{"key":"904_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.5664\/jcsm.3004","volume":"9","author":"T Roth","year":"2013","unstructured":"Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9:955\u201365.","journal-title":"J Clin Sleep Med"},{"key":"904_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pneurobio.2009.07.004","volume":"89","author":"M Mamelak","year":"2009","unstructured":"Mamelak M. Narcolepsy and depression and the neurobiology of gammahydroxybutyrate. Prog Neurobiol. 2009;89:193\u2013219.","journal-title":"Prog Neurobiol"},{"key":"904_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jad.2012.08.015","volume":"147","author":"CA Alfano","year":"2013","unstructured":"Alfano CA, Reynolds K, Scott N, et al. Polysomnographic sleep patterns of non-depressed, non-medicated children with generalized anxiety disorder. J Affect Disord. 2013;147:379\u201384.","journal-title":"J Affect Disord"},{"key":"904_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/NSS.S34838","volume":"5","author":"TA Hargens","year":"2013","unstructured":"Hargens TA, Kaleth AS, Edwards ES, et al. Association between sleep disorders, obesity, and exercise: a review. Nat Sci Sleep. 2013;5:27\u201335.","journal-title":"Nat Sci Sleep."},{"key":"904_CR8","doi-asserted-by":"publisher","first-page":"zsaa009","DOI":"10.1093\/sleep\/zsaa009","volume":"43","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Barateau L, Lopez R, et al. Narcolepsy Severity Scale: a reliable tool assessing symptom severity and consequences. Sleep. 2020;43:zsaa009.","journal-title":"Sleep"},{"key":"904_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","volume":"30","author":"TI Morgenthaler","year":"2007","unstructured":"Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30:1705\u201311.","journal-title":"Sleep"},{"key":"904_CR10","volume-title":"Xyrem (sodium oxybate oral solution, CIII)","author":"Jazz Pharmaceuticals","year":"2020","unstructured":"Jazz Pharmaceuticals. Xyrem (sodium oxybate oral solution, CIII). Full prescribing information. Palo Alto: Jazz Pharmaceuticals; 2020."},{"key":"904_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40263-016-0337-4","volume":"30","author":"L Barateau","year":"2016","unstructured":"Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30:369\u201379.","journal-title":"CNS Drugs"},{"key":"904_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5664\/jcsm.27994","volume":"6","author":"J Black","year":"2010","unstructured":"Black J, Pardi D, Hornfeldt CS, et al. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6:596\u2013602.","journal-title":"J Clin Sleep Med"},{"issue":"672","key":"904_CR13","first-page":"e1","volume":"43","author":"D Seiden","year":"2021","unstructured":"Seiden D, Tyler C, Dubow J. Pharmacokinetics of FT218, a once-nightly sodium oxybate formulation in healthy adults. Clin Ther. 2021;43(672):e1-14.","journal-title":"Clin Ther"},{"key":"904_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab200","author":"CA Kushida","year":"2021","unstructured":"Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep. 2021. https:\/\/doi.org\/10.1093\/sleep\/zsab200.","journal-title":"Sleep."},{"key":"904_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/sleep\/25.8.42","volume":"25","author":"U. S. Xyrem Multicenter Study Group","year":"2002","unstructured":"U. S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25:42\u20139.","journal-title":"Sleep"},{"key":"904_CR16","volume-title":"International classification of sleep disorders","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.","edition":"3"},{"key":"904_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.5664\/jcsm.6576","volume":"13","author":"RB Berry","year":"2017","unstructured":"Berry RB, Brooks R, Gamaldo C, et al. AASM scoring manual updates for 2017 (Version 2.4). J Clin Sleep Med. 2017;13:665\u20136.","journal-title":"J Clin Sleep Med"},{"key":"904_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/sleep\/13.6.479","volume":"13","author":"L Scrima","year":"1990","unstructured":"Scrima L, Hartman PG, Johnson FH Jr, et al. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep. 1990;13:479\u201390.","journal-title":"Sleep"},{"key":"904_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/sleep\/13.1.24","volume":"13","author":"O Lapierre","year":"1990","unstructured":"Lapierre O, Montplaisir J, Lamarre M, et al. The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. Sleep. 1990;13:24\u201330.","journal-title":"Sleep"},{"key":"904_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2869.1997.00221.x","volume":"6","author":"T Akerstedt","year":"1997","unstructured":"Akerstedt T, Hume K, Minors D, et al. Good sleep: its timing and physiological sleep characteristics. J Sleep Res. 1997;6:221\u20139.","journal-title":"J Sleep Res"},{"key":"904_CR21","doi-asserted-by":"publisher","first-page":"zsy256","DOI":"10.1093\/sleep\/zsy256","volume":"42","author":"A Parekh","year":"2019","unstructured":"Parekh A, Mullins AE, Kam K, et al. Slow-wave activity surrounding stage N2 K-complexes and daytime function measured by psychomotor vigilance test in obstructive sleep apnea. Sleep. 2019;42:zsy256.","journal-title":"Sleep"},{"key":"904_CR22","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.5664\/jcsm.5.2S.S6","volume":"5","author":"DJ Dijk","year":"2009","unstructured":"Dijk DJ. Regulation and functional correlates of slow wave sleep. J Clin Sleep Med. 2009;5:S6-15.","journal-title":"J Clin Sleep Med"},{"key":"904_CR23","doi-asserted-by":"publisher","first-page":"S538","DOI":"10.1016\/S0924-977X(06)70749-0","volume":"16","author":"DJ Dijk","year":"2006","unstructured":"Dijk DJ, Groeger J, Deacon S, et al. Association between individual differences in slow wave sleep, slow wave activity and sleep continuity in young, middle-aged and older men and women. Eur Neuropsychopharmacol. 2006;16:S538.","journal-title":"Eur Neuropsychopharmacol"},{"key":"904_CR24","doi-asserted-by":"publisher","first-page":"101488","DOI":"10.1016\/j.smrv.2021.101488","volume":"58","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Ren R, Yang L, et al. Polysomnographic nighttime features of narcolepsy: a systematic review and meta-analysis. Sleep Med Rev. 2021;58:101488.","journal-title":"Sleep Med Rev"},{"key":"904_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/157340310790231635","volume":"6","author":"M Nagai","year":"2010","unstructured":"Nagai M, Hoshide S, Kario K. Sleep duration as a risk factor for cardiovascular disease: a review of the recent literature. Curr Cardiol Rev. 2010;6:54\u201361.","journal-title":"Curr Cardiol Rev"},{"key":"904_CR26","doi-asserted-by":"publisher","first-page":"101440","DOI":"10.1016\/j.smrv.2021.101440","volume":"58","author":"PJ Jennum","year":"2021","unstructured":"Jennum PJ, Plazzi G, Silvani A, et al. Cardiovascular disorders in narcolepsy: review of associations and determinants. Sleep Med Rev. 2021;58:101440.","journal-title":"Sleep Med Rev"},{"key":"904_CR27","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1212\/WNL.0000000000004911","volume":"90","author":"A Bosco","year":"2018","unstructured":"Bosco A, Lopez R, Barateau L, et al. Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. Neurology. 2018;90:e479\u201391.","journal-title":"Neurology"},{"key":"904_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","volume":"34","author":"MJ Thorpy","year":"2020","unstructured":"Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34:9\u201327.","journal-title":"CNS Drugs"},{"key":"904_CR29","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17:1881\u201393.","journal-title":"J Clin Sleep Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00904-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00904-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00904-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T10:22:45Z","timestamp":1649499765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00904-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["904"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00904-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"23 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Avadel Ireland. Avadel was involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.\u00a0Open access publication was funded by Avadel Ireland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"TR is a consultant for Jazz Pharmaceuticals, Takeda Pharmaceutical Co., Orexo, Avadel Pharmaceuticals, Eisai, Merck & Co., and Idorsia. YD has served as a consultant or on advisory boards for Avadel Pharmaceuticals, Jazz Pharmaceuticals, UCB, Takeda Pharmaceutical Co., Theranexus, Harmony Biosciences, Bioprojet Pharma, and Idorsia. MJT has served as a consultant or on advisory boards for Axsome Therapeutics, Balance Therapeutics, Eisai, Avadel Pharmaceuticals, Harmony Biosciences, Jazz Pharmaceuticals, NLS Pharmaceuticals, Suven Life Sciences Ltd., and Takeda Pharmaceutical Co. CK is a consultant of Avadel Pharmaceuticals and XW Pharma. BCC is a member of the speakers bureaus and has received honoraria from Jazz Pharmaceuticals, Eisai, and Harmony Biosciences. He is an advisor and has received consulting fees and honoraria from Jazz Pharmaceuticals, Eisai,\u00a0Harmony Biosciences, and\u00a0Avadel Pharmaceuticals. He is a member of the speakers bureau for Merck & Co. Inc., Jazz Pharmaceuticals, Eisai, and Harmony Biosciences. RB is a shareholder in WaterMark Medical and Healthy Humming, LLC; serves on the board of directors for the National Sleep Foundation and WaterMark Medical; is a consultant for Jazz Pharmaceuticals, Takeda Pharmaceutical Co., Avadel Pharmaceuticals, and Oventus; has received industry-funded research grants from Avadel Pharmaceuticals, BrescoTec, Bayer, Idorsia, Suven Life Sciences Ltd, Jazz Pharmaceuticals, Balance, Vanda, Merck & Co., Eisai, Philips, FRESCA Medical, Takeda Pharmaceutical Co., LivaNova, Roche, and Sommetrics; and has served on speakers bureaus for Jazz Pharmaceuticals, Eisai, and Harmony Biosciences. RR received research grant funding by Avadel Pharmaceuticals to conduct the current study. He has also received research grant support from Jazz Pharmaceuticals, Eisai, Merck & Co., Apnimed, Inc., Idorsia, Biohaven, and Suven Life Sciences Ltd. He has participated in advisory boards for Jazz Pharmaceuticals, Eisai, and Harmony Biosciences. DS is an employee of Avadel Pharmaceuticals. JD is a consultant to, stockholder, and former employee of Avadel Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"The REST-ON protocol was approved by the centers\u2019 institutional review board or appropriate independent ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent (and assent for participants aged 16 or 17 years of age) before participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data underlying this article will be shared on reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TR, YD, JD, and DS participated in study conception and design. TR, YD, CK, MJT, BCC,\nRB, RR, JD, and DS participated in the acquisition and\/or analysis of data. TR, YD, CK, MJT, BCC, RB, RR, JD, and DS participated in drafting a significant portion of the manuscript or figures, approved the final version for submission, and agree to be accountable for the work presented.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}